Fundacio Privada Institucio Catalana De Recerca I Estudis Avancats

Fundacio Privada Institut D'investigacio Oncologica De Vall D'hebron

Fundacio Privada Institut D'investigacio Oncologica De Vall Hebron

Fundació Privada Institut De Recerca Hospital Universitari Vall Hebron

Fundació Privada Institució Catalana De Recerca I Estudis Avançants

Josep Lluis Parra Palau

José Baselga Torres

Joaquin Arribas Lopez

Kim Pedersen

Pier-Davide Angellini

Sirle Laos

Joaquín Arribas López

The present invention relates to a method of diagnosis and therapy of cancers expressing the HER2 receptor. The invention provides antibodies or fragments thereof that recognise an epitope of the HER2 receptor truncated form CTF-611, said epitope being defined by a sequence included in SEQ ID NO: 2, and that are capable of discriminating between CTF-611 and CTF-616 (represented by SEQ ID NO:7), preferably additionally capable of discriminating between CTF-611 and CTF-613 (represented by SEQ ID NO:6). The invention also provides a method of cancer diagnosis using the disclosed antibodies, which comprises the detection of the presence of the HER2 receptor truncated form consisting of the amino acid sequence SEQ ID NO: 1 in a patient sample.

Antibodies against HER2 truncated variant CTF-611

Growing community of inventors

Barcelona, Spain

Josep Lluis Parra Palau